fashion -WSS

fashion

author：focus 2025-08-23 05:55:54 - browse：15653

Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Security flaws in third

WSS

Secretariat’s lessons for human medicine

Congress may force more Covid

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

New study raises questions about niacin and heart health

Surprise medical billing ban raises prices elsewhere

Crowdfunding for unproven stem cell procedures spreads misinformation

leisure time

fashion

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

In 'major milestone,' FDA approves first cell therapy for solid tumors

Duchenne breakthrough therapy leaves behind pioneering families

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Canadians with cystic fibrosis outlive Americans by a decade

What does generative AI mean for health care? We asked experts

Abridge raises $150m as clinical notes automation market heats up

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

explore

FDA warns medical device makers about rise in fabricated data

A letter from the executive editor: The 2023 STATUS List

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Medicare Advantage enrollment hits roughly 33.4 million

A new drug could help frostbite victims avoid its ravages

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

focus

leisure time

hotspot

focus